Achilles Therapeutics plc, known by its ticker symbol ACHL, is a clinical-stage biopharmaceutical company dedicated to the development of novel cancer immunotherapies. The company is at the forefront of scientific research on the potential of neoantigen-targeted therapies, a new frontier in cancer treatment. These therapies aim to develop personalized treatments that leverage the immune system's ability to recognize and destroy cancerous cells which carry unique identifiers, called neoantigens.
The company was founded in 2016 by pioneering researchers in the field of oncology and genomics from the Francis Crick Institute and Cancer Research UK-UCL Cancer Institute. Headquartered in the United Kingdom, Achilles Therapeutics operates under the leadership of Dr. Iraj Ali, who brings over 20 years of experience in the biotech industry.
The firm’s lead programs, comprising of clonal neoantigen T cells (cNeT) are designed to target and destroy tumors promoting minimal residual disease, a key driver of cancer relapse. These cNeT products are developed for each individual patient using proprietary techniques to target and clonally select T cells. The company is currently advancing two programs, one in Non-Small Cell Lung Cancer (NSCLC) and the other one in Melanoma, which are in the phase I/IIa clinical trials stage.
Achilles Therapeutics has attracted significant attention from investors and industry specialists, indicating its potential future growth in the field of oncology research and therapeutics. The company has successfully raised substantial funding through several financing rounds, including its initial public offering in March 2021 on NASDAQ.
The company’s approach represents a promising new pathway in the treatment of cancers. By creating a personalized approach to immunotherapy, Achilles Therapeutics is developing therapies that are not just meant to manage cancer, but to aim for a cure, making the company a potential game-changer in oncology therapeutics.
In the broader context, ACHL observes rigorous compliance with safety, quality, and ethical standards, underscoring its commitment towards patients, healthcare providers, shareholders, and the general public. It is a member of the Biotechnology Innovation Organization (BIO), the world’s largest trade association representing biotechnology companies.
Furthermore, ACHL remains committed to scientific innovation and collaboration. With numerous ongoing research partnerships, the company is keen on expanding its scientific and clinical understanding of cancer biology, driving new therapeutic strategies and improving patient outcomes in the fight against cancer.
In essence, Achilles Therapeutics represents a robust and innovative player in the field of biopharmaceuticals, especially in the realm of immuno-oncology, committed to bringing forward breakthrough therapies for cancer patients worldwide.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
This article provides a news feed for Achilles Therapeutics plc (ACHL), compiling various biotech-related headlines from sources like Benzinga and Talk Markets. The news dates from April-May 2021 and covers topics such as daily biotech pulses, significant stock movers, and updates on company developments and regulatory decisions within the biotech industry.
Achilles Therapeutics plc announced its intention to voluntarily delist its American Depositary Shares (ADSs) from Nasdaq and deregister them with the SEC. This decision is connected to a planned members' voluntary liquidation, with a General Meeting scheduled for March 20, 2025, to obtain shareholder approval. The company expects its last trading day on Nasdaq to be March 20, 2025, after which trading would likely be limited to privately negotiated sales or over-the-counter markets.